← Back to patent-cliff list
CAS 204318-14-9
2-[4-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-4-{[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]carbamoyl}-2-phenylethyl]carbamoyl}methyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid
Codes: (I)664083-1-a
Application context (from source-drug indications)
Neuroendocrine tumourGa-68 EdotreotidePancreatic neuroendocrine tumourGa-68 EdotreotideDiagnostic agentGa-68 EdotreotideBreast cancerGa-68 EdotreotideSolid tumourGa-68 EdotreotideNasopharyngeal carcinomaGa-68 Edotreotide
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ga-68 Edotreotide | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-[4-({[(1R)-1-{[(4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-4-{[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl]carbamoyl}-2-phenylethyl]carbamoyl}methyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.